Treatment of gastric adenocarcinoma: A rapidly evolving landscape.
Claudin 18.2
Fibroblast growth factor receptor 2
Gastric adenocarcinoma
Gastroesophageal junction adenocarcinoma
HER-2
Immunotherapy
Microsatellite instability
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
18
07
2023
revised:
11
09
2023
accepted:
26
09
2023
medline:
27
11
2023
pubmed:
11
11
2023
entrez:
10
11
2023
Statut:
ppublish
Résumé
Gastric adenocarcinoma (GC) and gastroesophageal junction adenocarcinoma represent frequent and severe diseases whose management has radically changed over the last 10 years. With the advent of second- and third-line standard therapies for metastatic GC patients in the 2010s, the molecular dismemberment of the disease and positive trials with immunotherapy and targeted agents will mark the 2020s. New treatment options have emerged in the neoadjuvant, adjuvant, and metastatic setting. In addition to improved multimodal treatment in operable patients, new subgroups have emerged depending on molecular alterations (HER2, Microsatellite instability) or expression of specific proteins in the tumour (PDL1, Claudin 18.2) making immunohistochemistry central in profiling the tumour for an optimal individualised management. The aim of this review is to describe the current standards of management of early and late stage GC and the molecular markers needed today to optimally manage our patients together with future perspectives on this disease.
Identifiants
pubmed: 37948843
pii: S0959-8049(23)00672-X
doi: 10.1016/j.ejca.2023.113370
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113370Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest JT has received honoraria for speaker or advisory role from Sanofi, Roche, Merck Serono, Amgen, Servier, Pierre Fabre, Lilly, Astra Zeneca and MSD. JB has received honoraria for speaker or advisory role from AstraZeneca, Bristol-Myers Squibb, F. Hoffmann–La Roche Ltd, MSD, Novartis, Ipsen, Servier, Sanofi, Daiichi-Sankyo. FP-L has provided consultancy for AbbVie, Amgen, AstraZeneca, Bayer, BMS, Clovis, Daiichi Sankyo, Diaceutics, Eli Lilly, Illumina, Invitae, MSD, Novartis, Pfizer, Roche, and Ventana, and has received research grants from AbbVie, AstraZeneca, Bayer, BMS, Illumina, MSD, and Roche. ES has participated in consulting and/or advisory boards for Amgen, Astellas, Merck, Servier, MSD, BMS, Pierre Fabre, Daiichi Sankyo, Astra Zeneca, Bayer. AZ has participated in consulting and/or advisory boards for Amgen, Astellas, Merck, Roche, Sanofi, Servier, Baxter, MSD, BMS, Pierre Fabre, Zymeworks, Daiichi Sankyo, Astra Zeneca, Bayer, BeiGene. DB has nothing to disclose.